FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market

FDA has requested that the weight-loss drug Belviq, Belviq XR be withdrawn from the U.S. market because a safety clinical trial shows an increased occurrence of cancer. Stop taking the drug and talk to your health care professional if you have questions.

Source: FDA Center for Drug Evaluation and Research - What's New - February 13, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news